Jefferies Starts Liquidia Technologies (LQDA) at Buy

Jefferies analyst Matthew Andrews initiates coverage on Liquidia Technologies (NASDAQ: LQDA) with a Buy rating and a price target of $22.00.

The analyst comments "LQDA’s PRINT platform enables it to precisely control a drug particle’s shape/size with goals of improved PK/PD, safety and efficacy. Lead program LIQ861 is an inhalable dry powder (DPI) version of treprostinil for PAH. We see high likelihood of +ve Ph. III as the primary endpoint is safety at two wks and believe regulatory risk is lower as FDA has approved treprostinil four prior times (IV/
subcu, oral, nebulizer). Top-line data in H1 2019 is the key NT event."

For an analyst ratings summary and ratings history on Liquidia Technologies click here. For more ratings news on Liquidia Technologies click here.

Shares of Liquidia Technologies closed at $14.90 yesterday.

You May Also Be Interested In

• BofA Securities Downgrades Liquidia Technologies (LQDA) to Neutral
• Brookline Capital Markets Starts Edesa Biotech Inc. (EDSA) at Buy
• Cameco Corp. (CCO:CN) (CCJ) PT Raised at RBC Capital as 'Uranium continues to strengthen'